Literature DB >> 27275498

TG4010 immunotherapy: a novel weapon against advanced non-small cell lung cancer?

Ramon Andrade de Mello1.   

Abstract

Entities:  

Year:  2016        PMID： 27275498      PMCID： PMC4876279          DOI： 10.21037/atm.2016.04.16

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  9 in total

1.  Nivolumab for advanced squamous cell lung cancer: what are the next steps?

Authors:  Ramon Andrade de Mello; Inés Pousa; Deolinda Pereira
Journal:  Lancet Oncol       Date:  2015-02-20       Impact factor: 41.316

2.  Pembrolizumab for the treatment of non-small-cell lung cancer.

Authors:  Edward B Garon; Naiyer A Rizvi; Rina Hui; Natasha Leighl; Ani S Balmanoukian; Joseph Paul Eder; Amita Patnaik; Charu Aggarwal; Matthew Gubens; Leora Horn; Enric Carcereny; Myung-Ju Ahn; Enriqueta Felip; Jong-Seok Lee; Matthew D Hellmann; Omid Hamid; Jonathan W Goldman; Jean-Charles Soria; Marisa Dolled-Filhart; Ruth Z Rutledge; Jin Zhang; Jared K Lunceford; Reshma Rangwala; Gregory M Lubiniecki; Charlotte Roach; Kenneth Emancipator; Leena Gandhi
Journal:  N Engl J Med       Date:  2015-04-19       Impact factor: 91.245

3.  TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.

Authors:  Elisabeth Quoix; Hervé Lena; Gyorgy Losonczy; Frédéric Forget; Christos Chouaid; Zsolt Papai; Radj Gervais; Christian Ottensmeier; Aleksandra Szczesna; Andrzej Kazarnowicz; Joseph T Beck; Virginie Westeel; Enriqueta Felip; Didier Debieuvre; Anne Madroszyk; Julien Adam; Gisèle Lacoste; Annette Tavernaro; Bérangère Bastien; Céline Halluard; Tania Palanché; Jean-Marc Limacher
Journal:  Lancet Oncol       Date:  2015-12-23       Impact factor: 41.316

4.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Authors:  Benjamin J Solomon; Tony Mok; Dong-Wan Kim; Yi-Long Wu; Kazuhiko Nakagawa; Tarek Mekhail; Enriqueta Felip; Federico Cappuzzo; Jolanda Paolini; Tiziana Usari; Shrividya Iyer; Arlene Reisman; Keith D Wilner; Jennifer Tursi; Fiona Blackhall
Journal:  N Engl J Med       Date:  2014-12-04       Impact factor: 91.245

Review 5.  Immunotherapy and lung cancer: current developments and novel targeted therapies.

Authors:  Duarte Domingues; Alice Turner; Maria Dília Silva; Dânia Sofia Marques; Juan Carlos Mellidez; Luciano Wannesson; Giannis Mountzios; Ramon Andrade de Mello
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

6.  EGFR exon mutation distribution and outcome in non-small-cell lung cancer: a Portuguese retrospective study.

Authors:  Ramon Andrade de Mello; Filipa Soares Pires; Dânia Sofia Marques; Júlio Oliveira; Ana Rodrigues; Marta Soares; Isabel Azevedo; Ana Peixoto; Catarina Santos; Carla Pinto; Venceslau Hespanhol; Manuel R Teixeira; Teresina Amaro; Henrique Queiroga; António Araújo
Journal:  Tumour Biol       Date:  2012-07-29

7.  Cancer statistics, 2016.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2016-01-07       Impact factor: 508.702

Review 8.  EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer.

Authors:  Ramon Andrade de Mello; Pedro Madureira; Liliana S Carvalho; António Araújo; Mary O'Brien; Sanjay Popat
Journal:  Pharmacogenomics       Date:  2013-11       Impact factor: 2.533

Review 9.  Clinical and comparative utility of afatinib in non-small cell lung cancer.

Authors:  Manolo D'Arcangelo; Fred R Hirsch
Journal:  Biologics       Date:  2014-04-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.